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Abstract: Clostridium perfringens is a major cause of histotoxic and intestinal infections of humans
and other animals. This Gram-positive anaerobic bacterium can produce up to three sialidases
named NanH, NanI, and NanJ. The role of sialidases in histotoxic infections, such as gas gangrene
(clostridial myonecrosis), remains equivocal. However, recent in vitro studies suggest that NanI may
contribute to intestinal virulence by upregulating production of some toxins associated with intestinal
infection, increasing the binding and activity of some of those toxins, and enhancing adherence of
C. perfringens to intestinal cells. Possible contributions of NanI to intestinal colonization are further
supported by observations that the C. perfringens strains causing acute food poisoning in humans
often lack the nanI gene, while other C. perfringens strains causing chronic intestinal infections in
humans usually carry a nanI gene. Certain sialidase inhibitors have been shown to block NanI activity
and reduce C. perfringens adherence to cultured enterocyte-like cells, opening the possibility that
sialidase inhibitors could be useful therapeutics against C. perfringens intestinal infections. These
initial in vitro observations should be tested for their in vivo significance using animal models of
intestinal infections.
Keywords: Clostridium perfringens; intestinal infections; gas gangrene; toxins; sialidases;
sialidase inhibitors
1. An Introduction to Clostridium perfringens
Clostridium perfringens is present throughout the environment, including soil, sewage, feces, foods,
and the normal gastrointestinal flora of animals [1,2]. This Gram-positive, anaerobic, spore-forming
bacterium is also a feared pathogen of both humans and other animals [2,3]. The most notable
C. perfringens histotoxic infection is the rapidly-fatal human disease named clostridial myonecrosis
(traumatic gas gangrene) [4,5]. This bacterium is also a preeminent cause of common, and sometimes
lethal, infections originating in the intestines of humans or livestock [2,6]. Those intestinal infections
often involve damage to the small intestine, or to both the small intestine and colon, which results
in enteritis or enterocolitis, respectively [1,2]. C. perfringens intestinal infections can also progress to
enterotoxemia, where a toxin(s) is produced in the intestines and then absorbed to affect extraintestinal
organs such as the brain [2,7].
The virulence of this bacterium involves its ability to produce a vast toxin armory [2,3,8].
Currently ~20 different C. perfringens toxins have been identified, with more likely awaiting
discovery [8–15]. Toxin production repertoires vary greatly among different C. perfringens strains,
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permitting classification of these isolates into five types (A–E), based upon an isolate’s production of
four typing toxins (alpha, beta, iota, and epsilon toxins) (Table 1) [9,10].
Table 1. C. perfringens typing table.
Type
Toxin Production a
α β ε ι
A + − − −
B + + + −
C + + − −
D + − + −
E + − − +
a + indicates production of that toxin, while – indicates no production of that toxin.
C. perfringens type designations correlate with disease causation, as shown in Table 2. Two typing
toxins, i.e., beta toxin (CPB) and epsilon toxin (ETX), have proven importance in C. perfringens intestinal
infections of mammalian livestock [3,16,17]. C. perfringens produces other toxins that, while not used
for typing classification, are nonetheless important for infections originating in the intestines of
agriculturally-important animals. The foremost example is necrotic enteritis B (NetB) toxin, which is
critical when C. perfringens causes avian necrotic enteritis in poultry [12].
Table 2. Diseases associated with the major types/subtypes of C. perfringens.
Toxinotypes a Subtype Most Significant Diseases b
A
No CPE c or NetB production Human and animal myonecrosis (gas gangrene)
NetB-producing Necrotic enteritis of poultry
CPE-producing Human food poisoning and non-foodborne gastrointestinal disease
B Necro-hemorrhagic enteritis of sheep (lamb dysentery)
C Human enteritis necroticans (Darmbrand, pigbel); necrotic enteritis of neonatalindividuals of several animal species (e.g., cattle, sheep, pigs)
D Enterotoxemia of sheep and goats
E Suspected association with gastrointestinal disease of cattle, sheep and rabbits
a All types of C. perfringens may also produce several other toxins, including, but not limited to, beta2 toxin
(CPB2), perfringolysin O (PFO), and toxin C. perfringens large cytotoxin (TpeL); b Only diseases that have been
confirmed to be associated with each type of C. perfringens and significant in terms of prevalence are included in
this table; c CPE is C. perfringens enterotoxin.
With respect to human C. perfringens infections, type A strains are responsible for causing most
histotoxic infections. During gas gangrene, alpha toxin (CPA) plays the major role in virulence.
A non-typing toxin named PFO also contributes to this disease [4,5].
To date, only type A and C strains of C. perfringens have been conclusively linked to human
diseases originating in the intestines [1–3,18]. Type C strains use their CPB to cause enteritis
necroticans (EN), which was first described in post-World War II Germany, where it was referred to
as darmbrand [18–20]. In the 1960s–1970s, EN, known locally as pigbel, was a major cause of death
of children in the Papua New Guinea (PNG) Highlands [20,21]. Pigbel develops in children with
reduced trypsin levels due to predisposing conditions, including malnutrition, a diet rich in sweet
potato (which contains a trypsin inhibitor), and/or intestinal infections with pathogens producing
a trypsin inhibitor [20,21]. Their low intestinal trypsin levels render these children susceptible to
infection by type C strains because normal trypsin levels would otherwise easily inactivate CPB when
it is produced in the intestines. Consequently, children suffering from pigbel develop CPB-induced
necrotic enteritis or enterotoxemia and often die rapidly. The only treatment for pigbel is resection of
the bowel; however, this surgical intervention is only effective if performed early after the onset of
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infection [20,21]. A vaccine introduced in the 1980s dropped the incidence of pigbel dramatically in
PNG. Unfortunately, pigbel vaccination has since decreased and this illness may now be reappearing.
Although not used for typing classification, CPE is the toxin responsible for causing the
gastrointestinal symptoms of C. perfringens type A food poisoning (FP) [1,22]. This FP is currently
the 2nd most common bacterial foodborne disease in the USA, where one million cases occur
annually and economic losses approach $500 million/year [1,23]. In people with fecal impaction
or severe constipation due to side-effects from medications used to treat other pre-existing conditions,
C. perfringens type A FP can be much more severe and is often fatal [1,24]. Studies with animal models
suggest this may be due to absorption of CPE from the intestines, resulting in an enterotoxemia that
involves the liver and kidneys [24]. CPE-producing type A strains also cause about 5%–15% of all
cases of nonfoodborne human GI diseases, most notably antibiotic-associated diarrhea (AAD) [1,25].
As discussed later, CPE-associated AAD cases are more severe and longer lasting than typical
cases of C. perfringens type A FP, which usually self-resolve within 24 h [1,25]. While the cpe gene
can be either chromosomal or plasmid-borne in type A strains, most (~70%) type A FP strains carry
a chromosomal cpe gene [1]. In contrast, nearly 100% of type A AAD strains carry a plasmid cpe
gene [1]. There are also many other genetic differences between these two groups of type A cpe-positive
groups. For example, type A strains carrying a chromosomal cpe gene produce a unique small acid
soluble protein (SASP4) variant that provides their spores with greater resistance to heat, cold, and
chemical treatment and probably facilitates survival of these bacteria in the food environment [1,26,27].
Other differences between type A chromosomal cpe strains and type A plasmid cpe strains, particularly
with regard to sialidase gene carriage, will be discussed later.
In addition to its essential role during intestinal infections by type A cpe-positive strains, CPE may
also contribute to some cases of human EN caused by type C strains [18]. However, CPB is clearly of
critical importance for the pathogenesis of this disease [16].
2. C. perfringens Sialidases
Sialic acids are a carbohydrate family containing about 40 different nine-carbon relatives of
neuraminic acid [28,29]. Under physiological conditions, sialic acids are negatively charged [29].
N-acetylneuraminic acid (Neu5Ac), whose amino group is acetylated, is the most widespread sialic
acid [29,30]. Sialic acids are important components of the serum and mucus and represent the terminal
sugar residue of many glycan chains on host cell surfaces, where they are involved in cell- cell
recognition. Sialic acids can also stabilize enzymes or cell membrane proteins. Finally, due to their
negative charge, sialic acids can mediate binding and transport of positively-charged molecules [28–30].
Sialidases, also referred to as neuraminidases (E.C.3.2.1.18), are key enzymes that hydrolyze the
α-linkage of terminal sialic acids on various sialoglycoconjugates to generate free sialic acid [28–31].
Sialidases are made by certain viruses, microorganisms, and vertebrate animals, but not by plants.
Included amongst the sialidase-producing viruses and bacteria are several prominent pathogens,
e.g., influenza virus, Vibrio cholerae, Streptococcus pneumoniae, and C. perfringens. Sialidases can have
a nutritional function for normal flora or pathogenic bacteria [28,29,31]. In addition, they often
function directly as virulence factors during bacterial pathogenesis [30,32], as will be discussed later
for C. perfringens.
C. perfringens produces three different sialidases, which are named NanH, NanI, and NanJ [33].
NanH (43 kDa) lacks a secretion signal peptide and thus has a cytoplasmic location in log-phase
cultures [33,34]. In contrast, NanI (77 kDa) and NanJ (129 kDa) are secreted exosialidases ([33],
Figure 1). The catalytic modules of all three sialidases show conserved amino acid sequence identity
and belong to the family 33 carbohydrate binding module (CBMs, Figure 1) [35]. Compared to
NanH, which only consists of a catalytic domain, NanI and NanJ also possess additional accessory
carbohydrate-binding modules [35]. It is thought that these carbohydrate-binding domains increase
the binding affinity between NanI and NanJ and their polyvalent substrates. NanJ has a complex
multimodular structure comprised of a central catalytic module and five accessory modules [35].
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The two N-terminal modules show amino acid sequence identity with family 32 and family 40 CBMs.




Figure 1. Modular organization of  the C. perfringens  sialidases. CBM32  is a  carbohydrate binding 
module (CBM) belonging to the family 32 CBM; CBM40 is a module having an amino acid sequence 
identity with a family 40 CBM; GH33CM  is a family 33 CBM; UNK  is a module having unknown 
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Figure 1. Modular organization of the C. perfringens sialidases. CBM32 is a carbohydrate binding
module (CBM) belonging to the family 32 CBM; CBM40 is a module having an amino acid sequence
identity with a family 40 CBM; GH33CM is a family 33 CBM; UNK is a module having unknown
function; X82 is a family 82 “X module” of unknown function; FN3 is a module sharing distant identity
with fibronectin type III domains. The red small boxes are secretion signals. Modified with permission
from [35]. Copyright 2007 American Chemical Society.
t tr i s produce a l thr e sialidases (further discussion below). However,
as discussed in more detail later, some C. perfringens strains produce only one or t r
si li i l i s ll res si l f r ~ f t t l
si li se acti it [33,34,36,37].
o characterize the properties of the three . perfringe s siali ases, rece t st c str ct
series of isogenic mutants, wher two of the three sialid se genes present in C. perfringens type D strain
CN3718 were inactivated [33]. This strategy created mutants th t were each xpressing, at their native
levels, only NanJ, NanI, or NanH in a background free of contamination from the other two sialidases
to allow a precise characterization of the enzymatic proper es of each sialidase. N nI was found to
be more heat-t l rant comp red to N nJ or NanH, both of whic exhibited greatly reduced sialidase
activity at temperatur s above 43 ◦C [33]. In this experimental syste , all three sialidases worked best
at low pH conditions (pH ~5). The enzyme activity of each sialidase was hown to v ry in sensiti it
to various metal ions [33]. Furthermore, nlike the sialidases from Streptomyces sp ., C. p rfringens
sialidas s were found to be sensitive to p-chloromercuribenzoate, which reacts with thiol groups
in proteins [33]. Finally, the three C. perfringens sialidas s showed different substrate preferences.
NanI exhibited preferential activity in the order of α-2,3 > α-2,6 > α-2,8 sialic acid linkages and was
responsibl for most of the ac ivity in CN3718 supernatants that was directed against those sialic acid
linkages. Na J showed a preference for α-2,6 > α-2,8 > α-2,3 sialic acid linkages. Finally, NanH activit
was strongest for α-2,8 > α-2,3 > α-2,6 sialic acid linkages [33]. This diversity in linkage preferences
sugg sts that, when presen together, th three C. perfringens sialidases work in comb nation to generate
free sialic acid, ev from complex substrat s [33].
3. . perfringens iali ases: enetics and egulatio of x ressio
ll t ree . perfringens sialidases are encoded by chromosomal genes, althoug those genes
are located in different regions of the chromosome [38,39]. The sialidase-encoding ORFs in many
C. perfringens strains have now been sequenced. Those sequencing a alyses i icate t at, a o gst
ifferent . perfringens strai s, t e a J seq e ce s ares 96 to 100 i e tity, t e a I seq e ce as
98 to 100 i e tity, and the NanH sequence shares 93% to 100% identity [34,38,39].
s tr e for their toxin productio , . perfri ge s strai s ar i t eir atter s of siali ase
r cti . st strai s r ce all t ree siali ases, it a I s all ei res si le f r st
of t e siali ase acti it i c lt re s er ata ts of t ose . perfri ge s strai s [34,36]. o e er, a I
r cti is t esse tial f r . perfri ge s r t si ce s e strai s f t is bacteri at rall
lac t e a I e e [36]. I teresti l , t e a I e e is c siste tl a se t fr t e t e strai s
carr i a c r s al cpe gene, as well as the genetically related type C darmbrand strains [36].
In contrast, the anI gene is carried by most plasmid cpe-carrying type AAD strains, cpe-negative
type A normal human intestinal flora strains, and type C pig-bel strains [36]. Since NanI is s all t e
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major sialidase of C. perfringens, it is not surprising that exosialidase activity is typically significantly
lower for naturally nanI-negative strains compared to strains carrying a nanI gene [36]. The potential
pathogenic importance of these differences will be discussed later.
Most type A FP strains with a chromosomal cpe gene lack the nanJ gene, as well as the nanI gene.
However, those typical FP strains do carry the nanH gene. It should be noted that occasional strains of
C. perfringens besides the type A chromosomal cpe FP strains or type C darmbrand strains also lack a
sialidase gene. For example, Strain 13 is a cpe-negative type A strain that can cause gas gangrene yet it
lacks the nanH gene [37,40].
The regulation of sialidase production by C. perfringens is complicated (Figure 2). A number of
regulators influencing expression of one or more sialidase genes have been identified. For example,
the VirS/VirR two-component signal transduction system was shown to upregulate nanI and
nanJ expression [41]. Rather than a direct regulatory effect involving VirS binding to sialidase
gene promoters, this VirS/R two-component system positively controls expression of the vrr gene,
which encodes virR-regulated RNA (VR-RNA). This regulatory RNA then modulates sialidase gene
expression [42]. ReeS is another sensor kinase whose presence also increases nanI and nanJ sialidase
gene expression by a putative response regulator, referred to as ReeR [43]. In contrast, a transcriptional
regulator named RevR has different regulatory effects on nanJ and nanI expression, possibly via
a proposed sensor kinase named RevS. RevR increases nanJ expression, but negatively regulates
nanI expression [44]. Finally, using a codY null mutant of C. perfringens type D strain CN3718,
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Figure 2. A prop sed model f r regulation of expression of sialidase genes and the pathway for
sialic acid etabolism in C. perfringens. Exosialidases generate free sialic acid from mucus or host cell
surfaces [33,40]. The free sialic acid is then transported into C. perfringens where it is metabolized to
fructose-6-P [40]. There is evidence that VirS/VirR, RevR, ReeS, NanR, and CodY systems directly
or indirectly affect sialidase production, although inter-relationships between these regulators are
unclear [40,41,43–46]. The VirS/VirR two component system acts as a positive regulator of the vrr
gene, which encodes VR-RNA. VR-RNA is then a positive regulator of nanI and nanJ expression [41,42].
The ReeS sensor kinase positively regulates nanI and nanJ gene expression, presumably by a putative
transcriptional r gulator named ReeR [ 3]. RevS positively regulates anJ expression but negatively
regulates anI expression [44]. CodY represses nanH and nanJ expression [45]. Based on sequence
homology comparison with similar regulators in other bacteria, NanR may repress nanI expr ssion
and the sialic acid metabolism pathway, but there is no direct experimental evidence yet to support
this hypothesis. Green lines indicate positive regulation while red lines indicate negative regulation.
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No proven regulator has yet been identified that directly modulates sialidase production by
binding to the promoters of C. perfringens sialidase genes. However, gel mobility shift assays have
demonstrated high affinity binding of a purified protein named NanR to DNA from the promoter
region of the nanI gene [40]. Since NanR has homology with the ribose-5-phosphate isomerase B
regulator (RpiR) family of transcriptional repressors known to control sialidase production in bacteria
such as E. coli, Vibrio vulnifcus, and Staphylococcus aureus, this result suggests that NanR may be
involved in nanI expression regulation [31,40,47]. Consistent with its potential involvement in sialic
acid generation and usage, NanR lies within a six-gene operon encoding the complete pathway for
transport and metabolism of sialic acid by C. perfringens [40]. As discussed in more detail below,
this operon also encodes NanE (epimerase) and NanA (sialic acid lyase) enzymes.
For the nanI and nanJ genes, primer extension analyses identified three or two putative
transcription start sites, respectively [40]. These promoters are located within ~500 bp of the start
codons of nanI and nanJ. This multiplicity of promoters may provide one explanation for why so many
different regulators control sialidase expression, although (as mentioned) detailed understanding of
regulator binding to these promoter sequences is currently lacking [40].
Only a limited number of bacterial species, mainly those having a close association with the
sialic acid-rich environment of the host, can utilize Neu5Ac [48]. C. perfringens was actually the first
bacterium demonstrated to be capable of utilizing a sialic acid (Neu5Ac) as a carbon source [31].
This result was later confirmed by another study showing that Neu5Ac can be used by C. perfringens
when growing in a semi-defined medium [31]. It was also recently found that NanI and NanJ,
but not NanH, can cause the release of sialic acid from Caco-2 cells [33]. This effect may contribute
to pathogenesis, since these sialidases could help C. perfringens obtain nutrients in vivo by releasing
sialic acid from glycolipids or glycoproteins on the host cell surface or in mucus. Interestingly, contact
with Caco-2 cells was shown to upregulate the expression of NanI [34], which could potentiate NanI
contributions during intestinal infections, as discussed later.
NanI, but not NanJ, production is induced by the addition of Neu5Ac to a medium [40].
As introduced earlier, NanR is part of an operon that encodes a complete pathway for the transport
and metabolism of sialic acid. After sialic acid is generated by sialidases, it is then transported and
metabolized by products of this operon, also referred to as the Nan cluster. This process involves an
initial conversion of sialic acid to N-acetyl glucosamine, followed by metabolism of that carbohydrate to
fructose-6-P, which C. perfringens can use as carbon sources and for energy production (Figure 2) [40,46].
Many other pathogenic and commensal bacteria found in the intestines carry a Nan
cluster for sialic acid utilization [48]. Examples of such bacteria include Vibrio cholerae and
Salmonella enterica [48,49]. Many of these bacteria capable of utilizing sialic acid also colonize the
human or animal intestinal tract. This correlation is probably not a coincidence since sialic acid is
a component of mucin, the major protein in mucus, which is abundant in the human and animal
intestines [48]. However, to generate free sialic acid from mucus for uptake and metabolism inside the
bacterial cell, extracellular sialidases must be present in the intestinal environment. Interestingly, some
pathogenic bacteria, e.g., C. difficile, have a Nan cluster but do not produce their own sialidase. Instead,
it is believed that C. difficile uses free sialic acid generated in the intestines by sialidases produced by
other bacteria, such as Bacteroides thetaiotaomicron [50,51].
4. Possible Contributions of Sialidases to C. perfringens Diseases
Some pathogens use sialic acids to coat their cell surface, the flagellum, the capsule polysaccharide,
or the lipopolysaccharide. This masks these bacteria so they can avoid the host immune system
defense [28]. Whether C. perfringens coats its surface with host-derived sialic acid has not been studied,
to our knowledge.
Sialidases can also promote in vivo growth and colonization of bacterial pathogens [30].
For extraintestinal infections, an example is the major human respiratory tract pathogen
Streptococcus pneumoniae, which encodes up to three sialidases, named NanA, NanB, and NanC.
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NanA is the predominant sialidase that removes the sialic acid Neu5Ac from a variety of
glycoconjugates. NanB is an intramolecular trans-sialidase producing 2,7-anhydro-Neu5Ac
selectively from α2,3-sialosides, while NanC produces 2-deoxy-2,3-didehydro-N-acetylneuraminic
acid (Neu5Ac2en), which can be hydrated to Neu5Ac. The three pneumococcal sialidases share a
common catalytic mechanism up to the final product formation step, and all three sialidases are
implicated in pathogenesis, including colonization, and are potential drug targets [52]. S. pneumoniae
then takes up and metabolizes sialic acid using a similar pathway as present in C. perfringens [40].
The contribution of sialidases to growth and colonization during extraintestinal infections caused
by C. perfringens is unclear. One study demonstrated that a nanJ and nanI double null mutant of
C. perfringens strain 13 remains fully virulent in the mouse myonecrosis model [37]. This result could
suggest that Neu5Ac metabolism is not essential for growth or colonization by C. perfringens in muscle.
However, as noted in that study [37], this result does not necessarily preclude subtle contributions of
sialidases to colonization or growth since the mouse myonecrosis model requires a massive inoculum
that may mask such contributions.
Increasing evidence indicates that sialidases and sialic acid often play significant roles in growth
and colonization of the intestines by bacterial pathogens [34,49,52,53]. For example, sialic acid appears
to be an important source of carbon and energy for survival, growth and adherence of E. coli in the
gastrointestinal system [54]. Similarly, catabolism of sialic acid by V. cholerae plays a significant
role in both in vitro and in vivo colonization and growth [49]. In addition, V. cholerae sialidase
enhances the binding and uptake of cholera toxin [55]. In V. vulnificus, a Nan utilization system
is also important for bacterial colonization and growth in the intestines [56]. The sialidase NanS play a
role in Clostridium sordellii adhesion and enhances Non-TcsL mediated cytotoxicity [53]. As mentioned
above, C. difficile uses sialic acid generated by sialidases of other bacteria to grow and persist in the
intestines [50,51].
As mentioned earlier, NanI may contribute to in vivo growth. Contact of C. perfringens with
Caco-2 cells increases the production of this enzyme [34] and NanI can induce the release of free
sialic acids from enterocyte-like Caco-2 cells [33]. Since C. perfringens possesses a sialic acid utilization
system, similar NanI-generated sialic acid in the intestines should be useful for in vivo growth of
this bacterium.
Earlier studies demonstrated that NanI production also impacts the production of several
C. perfringens toxins [34,37,57]. Specifically, inactivating the nanI gene in C. perfringens type A strain 13
caused a slight increase in supernatant activities of alpha toxin and perfringolysin O (PFO), which
are contributors to gas gangrene [37], but their role (if any) in most intestinal infections, particularly
human infections, is unsettled [3]. However, it was later demonstrated that inactivating the nanI gene
in type D strain CN3718 reduced ETX toxin production in vitro and that either genetic or physical
complementation could recover this ETX production [57]. NanI effects on ETX production involved
reductions in both codY and ccpA transcript levels, suggesting a model whereby NanI generates sialic
acid release in the intestines and that free sialic acid then alerts a type D strain of its presence in the
intestines, making it worthwhile for this bacterium to upregulate ETX production to induce disease.
There have been only limited studies to date on the effects of C. perfringens sialidase on toxin
action, particularly on those toxins important for intestinal infections. An exception is ETX, where
conclusions from early studies had been contradictory. One early study [58] reported that sialidases
enhance ETX cytotoxicity towards Madin-Derby Canine Kidney (MDCK) epithelial cells, while a
second study [59] reported that pretreating synaptosomal membranes with sialidases lowers their
subsequent ETX binding levels. Recently a study used purified NanI, as well as nanI, nanJ, or nanH
single null mutants, a nanI/nanJ double null mutant, and a triple sialidase null mutant, to study
possible sialidase enhancement of ETX action [34]. Results obtained [34] conclusively showed that
NanI sialidase increases the ETX sensitivity of MDCK cells and that this effect involves an increase in
ETX binding levels. The mechanism of this enhancement is not yet clear but it could involve either
NanI increasing the exposure of ETX receptors on the host cell surface or NanI modifying the host cell
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surface charge to increase binding of this toxin. Whether a similar effect extends to other C. perfringens
toxins active during intestinal infections is not yet clear.
Only limited studies have addressed the mechanism of C. perfringens adherence to host cells and
tissues [60–62]. For example, the adhesins used by C. perfringens in vivo remain unclear. However,
some strains produce a collagen adhesion protein (CNA), and/or fibronectin binding proteins (FbpA,
FbpB) that have been implicated in adhesion and colonization [60–63].
Sialidases are known to contribute to the ability of some bacterial pathogens to adhere to host
cells, tissues, or mucosal surfaces in the airways or intestines [30]. A recent in vitro study suggests
sialidase contributions to C. perfringens intestinal adherence [34]. That study [34] demonstrated that
type D strain CN3718 attaches to cultured Caco-2 enterocyte-like cells. This adhesion was specific since
this intestinal disease strain exhibited significantly less adherence to fibroblasts and kidney cells [34].
Interestingly, the attachment of CN3718 to Caco-2 cells is greatly facilitated by NanI production
(Figure 3). Wild-type CN3718 exhibited much more adherence to Caco-2 cells compared to an isogenic
triple mutant strain that does not produce any sialidase. Complementation studies showed that, of
the three sialidases made by CN3718, restoring NanI production to the triple sialidase mutant yielded
the greatest enhancement of adherence. That result indicated that NanI is of prime importance for
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NanI on both  charge and  epithelial barrier  integrity  could help  to  increase  toxin binding  and C. 
perfringens colonization. A C. perfringens sialidase  (not specified) has,  in fact, been shown  to affect 
Figure 3. Adhesion of C. perfringens CN3718 to Caco-2 cells [34]. Caco-2 cells were incubated for 2 h at
37 ◦C under anaerobic conditions. C. perfringens CN3718 produces all three sialidases. This wild-type
(WT) strain, and a complementing strain that produces only NanI, attach very well to Caco-2 cells as
detected by immunofluorescence microscopy (600×). In comparison, only a few cells of an isogenic
mutant with all three sialidase genes disrupted were able to attach to Caco-2 cells. Furthermore, when
the triple mutant was complemented to produce only NanJ or NanH, those bacteria remained poorly
adherent (not shown). Green: C. perfri gens; Red: Caco-2 cells. Reproduced with permission from [34].
Creativ Commons License 2011, Copyright J. Li and B.A. McClane.
However, NanI itself does not appear to be a significant adhesin since the CN3718 codY null
mutant shows 50% less adherence to Caco-2 cells compared to wild-type CN3718, despite this mutant
producing the same levels of NanI as the wild-type strain [45]. This result suggests a two-step
adherence mechanism. First, secreted NanI modifies the Caco-2 enterocyte-cell surface, which then
allows the unknown adhesin present on the surface of C. perfringens to more easily bind to the still
unidentified receptor(s) on the enterocyte-cell surface.
Sialidases may enhance C. perfringens adherence to host cells via both nonspecific and specific
mechanisms. Sialic acids, typically present at the distal ends of carbohydrate chains, are negatively
charged carbohydrates [28,30]. In addition, terminal sialic acids promote endothelial barrier integrity,
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so treatment of epithelial monolayers with C. perfringens sialidases may lead to barrier disruption
and may increase access for C. perfringens so they can adhere [64]. Therefore, nonspecific effects of
secreted NanI on both charge and epithelial barrier integrity could help to increase toxin binding and
C. perfringens colonization. A C. perfringens sialidase (not specified) has, in fact, been shown to affect
barrier resistance in some, but not all, host cells [64]. However, for some cell lines, nonspecific effects
do not appear to completely explain NanI enhancement of C. perfringens adherence. As mentioned,
C. perfringens CN3718 exhibits much greater adhesion for certain mammalian cells, such as Caco-2
and HT-29 intestinal cell lines, than for cell lines of nonintestinal origin [34]. Similarly, the toxins
involved in C. perfringens intestinal infections only bind to and affect certain cells. Those observations
suggest that NanI can also have specific effects in promoting C. perfringens adherence and toxin binding.
This could involve specific effects of NanI sialidase on modifying host cell surface adhesins/toxin
receptors and/or trimming back nearby molecules to better unmask the adhesin or toxin receptor on
host cell surfaces.
When C. perfringens causes diseases originating in the intestines, its secreted proteins come
into contact with host proteases, such as trypsin, that are present in the intestinal lumen. While
some C. perfringens proteins, e.g., CPB, are highly sensitive to intestinal proteases [16], other proteins
secreted by this bacterium are proteolytically-activated in the intestines. A prime example of a
proteolytically-activated C. perfringens protein is ETX, which is initially produced as an inactive
prototoxin and then activated by intestinal trypsin, chymotrypsin, and carboxypeptidases that remove
N- and C-terminus residues from the prototoxin [65]. Similarly, trypsin or chymotrypsin treatment of
CPE also increases cytotoxicity, in this case by removing N-terminal sequences from the native CPE
protein to facilitate toxin oligomerization during pore formation [66]. Interestingly, NanI (but not NanJ
or NanH) can also be proteolytically-activated by trypsin [33,34]. The increased enzymatic activity
of trypsin-activated NanI was shown to be substrate-specific [33]. Collectively, these observations
suggest that trypsin activation of NanI may contribute to C. perfringens intestinal diseases.
While NanI can enhance C. perfringens adherence and toxin binding, typical type A FP strains,
i.e., those with a chromosomal cpe gene, do not carry the nanI gene. Furthermore, those typical FP
strains possess very low exosialidase activities [36]. The limited production of sialidases by type A
FP strains obviously does not hinder their ability to cause food-borne intestinal diseases. Unlike the
typical FP strains, nearly all type A AAD strains do carry a nanI gene. When a nanI null mutant of a
type A AAD strain was characterized, this nanI null mutant was shown to enter the sporulation cycle
earlier and to produce more CPE than its wild-type parent. This finding supports the dispensability of
NanI for the typical FP strains, which cause an acute disease. During the acute FP, NanI would not
be needed for nutritional purposes or to enhance bacteria adherence or colonization since the typical
FP strains are ingested in very large numbers in contaminated food, then quickly sporulate in the
intestines to produce CPE, induce diarrhea via that CPE, and exit from the intestines via the flushing
action of diarrhea (Figure 4) [36]. In contrast, type A AAD or sporadic diarrhea (SD) strains with a
plasmid cpe gene cause chronic gastrointestinal disease lasting up to several weeks, so in vivo growth
and colonization is important for their persistence. Those Type A AAD or SD strains may use NanI
for their growth and colonization, as necessary to achieve the persistence required to cause a chronic
diarrhea (Figure 4) [36].
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Figure 4. Possible models for acute C. perfringens type A FP vs. chronic gastrointestinal diseases like
AAD. (A) C. perfringens type A FP does not require NanI production because strains are ingested in
large amounts, sporulate in vivo to produce CPE and are then quickly removed from the intestines by
diarrhea. (B) C. perfringens type A AAD does involve NanI production, which may promote adherence
and colonization, as required for chronic diarrhea. Modified with permission from [36]. Copyright
2014 American Society for Microbiology.
5. Sialidase Inhibitors: Potential Therapeutic Agents?
As described above, sialidases may offer several contributions to C. perfringens pathogenesis,
particularly during intestinal infections. C. perfringens diseases are challenging to treat with
antibiotics because already-synthesized toxins will continue to work even after the administration
of antibiotics. Similarly, it is often difficult to treat or prevent C. perfringens infections with vaccines
or neutralizing antibodies because some individual strains produce multiple (up to five) different
toxins [2,3]. Those factors suggest that sialidase inhibitors represent interesting potential candidates
for drug development.
Sialidase inhibitors have proven to be efficacious for the treatment of some infectious disease [67].
The most notable clinical application of sialidase inhibitors are several sialidase inhibitors (Zanamivir,
Oseltamivir, Peramivir (Rapivab)) that are currently used for treating infections involving influenza
virus [67]. However, there is also precedent for sialidase inhibitors interfering with bacterial growth
and adhesion. Oseltamivir reduced the growth and adherence of Tannerella forsythia, which causes
periodontitis, by two- to three-fold [68].
Two classic sialidase inhibitors, i.e., Siastatin B (SB) and N-acetyl-2,3-dehydro-2-deoxyneuraminic
acid (NADNA), have been tested against C. perfringens [33,36,57,69,70]. SB, a broad-spectrum sialidase
inhibitor isolated from a Streptomyces spp. culture, is an unusual 6-acetamido-3-piperidinecarboxy
late [70]. NADNA is an analogue of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid that is modified
at the C-4 position. NADNA can inhibit the sialidase activity from influenza viruses A and B,
parainfluenza 2 virus, Vibrio cholerae, Arthrobacter ureafaciens, C. perfringens, and sheep liver [69].
A recent study measured the effects of SB and NADNA on sialidase activities of overnight culture
supernatants of C. perfringens CN3718 mutants ENanJ, ENanI, or ENanH, which contain natural levels
of only NanJ, NanI, or NanH, respectively [33]. NanI was the most sensitive sialidase to both NADNA
and SB, while NanH was the least sensitive sialidase to these inhibitors; IC50s for these inhibitors are
shown in Table 3 [33].
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Table 3. Effect of sialidase inhibition on sialidase activity (IC50).
Sample NADNA (IC50) Siastatin B (IC50)
CN3718 18.9 µM 42.2 µM
ENanJ 12.4 µM 15.1 µM
ENanI 13.4 µM 27.5 µM
ENanH 44.6 µM 50.9 µM
Reproduced with permission from [33]. Copyright 2014 American Society for Microbiology.
It was also shown that the adherence of C. perfringens AAD strain F4969 to Caco-2 cells can
be reduced by either SB or NADNA [36]. In addition, both NADNA and SB efficiently inhibited
sialidase activity in bacterial cell-free supernatants collected from C. perfringens type D strain CN3718.
Consistent with those results, CN3718 cultures grown in the presence of the SB inhibitor also exhibited
substantially reduced culture sialidase activity and ETX production. However, the NADNA sialidase
inhibitor did not inhibit sialidase activity in CN3718 cultures, even at very high doses of the inhibitor.
In the presence of NADNA, CN3718 cultures still possessed strong sialidase activity and also made
the same amounts of ETX as wild-type CN3718 grown in the absence of any sialidase inhibitor [57].
Collectively, these results suggest that at least some sialidase inhibitors may be potentially useful
therapeutics against C. perfringens infections.
6. Concluding Remarks and Future Directions
Most studies of C. perfringens virulence have, correctly, focused on toxin contributions. Only a
few in vivo studies have thus far examined the role of exoenzymes in C. perfringens pathogenesis and
their results have been equivocal. However, those studies examined the possible role of sialidases
in gas gangrene. Recent in vitro studies suggest that sialidases, particularly NanI, may be important
contributors to C. perfringens intestinal infections. Those contributions could include upregulated
production of some toxins relevant to intestinal infections, enhanced binding and activity of some of
those toxins, increased adherence of C. perfringens to host cells, and possibly generation of substrates
for growth and metabolism [33,34,36,57]. There is a clear need to move these promising findings into
appropriate animal models to firmly evaluate sialidase contributions to C. perfringens virulence.
In vitro studies also suggest that some sialidase inhibitors might be useful therapeutics for treating
C. perfringens infections originating in the intestines [57]. This possibility also needs to be evaluated
in animals. Identification of more potent inhibitors of C. perfringens sialidases may be helpful for
those studies.
Acknowledgments: Preparation of this review was supported, in part, by a grant from the National Institute of
Allergy and Infectious Disease (R21 AI125796-1).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. McClane, B.A.; Robertson, S.L.; Li, J. Clostridium perfringens. In Food Microbiology: Fundamentals and Frontiers,
4th ed.; Doyle, M.P., Buchanan, R.L., Eds.; ASM Press: Washington, DC, USA, 2013; pp. 465–489.
2. McClane, B.A.; Uzal, F.A.; Miyakawa, M.F.; Lyerly, D.; Wilkins, T.D. The enterotoxic clostridia.
In The Prokaryotes, 3rd ed.; Dworkin, M., Falkow, S., Rosenburg, E., Schleifer, H., Stackebrandt, E., Eds.;
Springer: New York, NY, USA, 2006; pp. 688–752.
3. Uzal, F.A.; Freedman, J.C.; Shrestha, A.; Theoret, J.R.; Garcia, J.; Awad, M.M.; Adams, V.; Moore, R.J.;
Rood, J.I.; McClane, B.A. Towards an understanding of the role of Clostridium perfringens toxins in human
and animal disease. Future Microbiol. 2014, 9, 361–377. [CrossRef] [PubMed]
4. Rood, J.I. Clostridium perfringens and histotoxic disease. In The prokaryotes: A Handbook on the Biology of
Bacteria, 3rd ed.; Dworkin, M., Falkow, S., Rosenberg, E., Schleifer, K.-H., Stackebrandt, E., Eds.; Springer:
New York, NY, USA, 2007; Volume 4, pp. 753–770.
Toxins 2016, 8, 341 12 of 15
5. Titball, R.W.; Rood, J.I. Clostridium pefringens: Wound indections. In Molecular Medical Microbiology;
Sussman, M., Ed.; Academic Press: London, UK, 2002; pp. 1875–1903.
6. Uzal, F.A.; Vidal, J.E.; McClane, B.A.; Gurjar, A.A. Clostridium perfringens toxins involved in mammalian
veterinary diseases. Open toxinol. J. 2010, 2, 24–42. [CrossRef]
7. Songer, J.G. Clostridial enteric diseases of domestic animals. Clin. Microbiol. Rev. 1996, 9, 216–234. [PubMed]
8. Hatheway, C. Toxigenic clostridia. Clin. Microb. Rev. 1990, 3, 66–76. [CrossRef]
9. McDonel, J.L. Toxins of Clostridium perfringens types A, B, C, D, and E. In Pharmacology of Bacterial Toxins;
Dorner, F., Drews, H., Eds.; Pergamon Press: Oxford, UK, 1986; pp. 477–517.
10. Petit, L.; Gilbert, M.; Popoff, M. Clostridium perfringens: Toxinotype and genotype. Trends Microbiol. 1999, 7,
104–110. [CrossRef]
11. Animoto, K.; Noro, T.; Oishi, E.; Shimizu, M. A novel toxin homologous to large clostridial cytotoxins
found in culture supernatant of Clostridium perfringens type C. Microbiology 2007, 153, 1198–1206. [CrossRef]
[PubMed]
12. Keyburn, A.L.; Boyce, J.D.; Vaz, P.; Bannam, T.L.; Ford, M.E.; Parker, D.; Di Rubbo, A.; Rood, J.I.;
Moore, R.J. NetB, a new toxin that is associated with avian necrotic enteritis caused by Clostridium perfringens.
PLoS Pathog. 2008, 4, e26. [CrossRef] [PubMed]
13. Mehdizadeh Gohari, I.; Parreira, V.R.; Timoney, J.F.; Fallon, L.; Slovis, N.; Prescott, J.F. NetF-positive
Clostridium perfringens in neonatal foal necrotising enteritis in kentucky. Vet. Rec. 2016, 178, 216. [CrossRef]
[PubMed]
14. Yonogi, S.; Matsuda, S.; Kawai, T.; Yoda, T.; Harada, T.; Kumeda, Y.; Gotoh, K.; Hiyoshi, H.; Nakamura, S.;
Kodama, T.; et al. BEC, a novel enterotoxin of Clostridium perfringens found in human clinical isolates from
acute gastroenteritis outbreaks. Infect Immun. 2014, 82, 2390–2399. [CrossRef] [PubMed]
15. Irikura, D.; Monma, C.; Suzuki, Y.; Nakama, A.; Kai, A.; Fukui-Miyazaki, A.; Horiguchi, Y.; Yoshinari, T.;
Sugita-Konishi, Y.; Kamata, Y. Identification and characterization of a new enterotoxin produced by
Clostridium perfringens isolated from food poisoning outbreaks. PLoS ONE 2015, 10, e0138183. [CrossRef]
[PubMed]
16. Sayeed, S.; Uzal, F.A.; Fisher, D.J.; Saputo, J.; Vidal, J.E.; Chen, Y.; Gupta, P.; Rood, J.I.; McClane, B.A. Beta
toxin is essential for the intestinal virulence of Clostridium perfringens type C disease isolate CN3685 in a
rabbit ileal loop model. Mol. Microbiol. 2008, 67, 15–30. [CrossRef] [PubMed]
17. Garcia, J.P.; Adams, V.; Beingesser, J.; Hughes, M.L.; Poon, R.; Lyras, D.; Hill, A.; McClane, B.A.; Rood, J.I.;
Uzal, F.A. Epsilon toxin is essential for the virulence of Clostridium perfringens type D infection in sheep,
goats and mice. Infect Immun. 2013, 81, 2405–2414. [CrossRef] [PubMed]
18. Ma, M.; Gurjar, A.; Theoret, J.R.; Garcia, J.P.; Beingesser, J.; Freedman, J.C.; Fisher, D.J.; McClane, B.A.;
Uzal, F.A. Synergistic effects of Clostridium perfringens enterotoxin and beta toxin in rabbit small intestinal
loops. Infect Immun. 2014, 82, 2958–2970. [CrossRef] [PubMed]
19. Ma, M.; Li, J.; McClane, B.A. Genotypic and phenotypic characterization of Clostridium perfringens isolates
from darmbrand cases in post-World War II Germany. Infect Immun. 2012, 80, 4354–4363. [CrossRef]
[PubMed]
20. Lawrence, G.W. The pathogenesis of enteritis necroticans. In The Clostridia: Molecular Genetics and Pathogenesis;
Rood, J.I., McClane, B.A., Songer, J.G., Titball, R.W., Eds.; Academic Press: London, UK, 1997; pp. 198–207.
21. Johnson, S.; Gerding, D.N. Enterotoxemic infections. In The Clostridia: Molecular Biology and Pathogenesis;
Rood, J.I., McClane, B.A., Songer, J.G., Titball, R.W., Eds.; Academic Press: London, UK, 1997; pp. 117–140.
22. Freedman, J.C.; Shrestha, A.; McClane, B.A. Clostridium perfringens enterotoxin: Action, genetics, and
translational applications. Toxins 2016, 8. [CrossRef] [PubMed]
23. Centers for Disease Control and Prevention (CDC). Posting date. CDC estimates of foodborne illness in
the United States: Clostridium perfringens. Available online: http://www.cdc.gov/foodsafety/diseases/
clostridium-perfringens.html (accessed on 28 July 2016).
24. Caserta, J.A.; Robertson, S.L.; Saputo, J.; Shrestha, A.; McClane, B.A.; Uzal, F.A. Development and
application of a mouse intestinal loop model to study the in vivo action of Clostridium perfringens enterotoxin.
Infect. Immun. 2011, 79, 3020–3027. [CrossRef] [PubMed]
25. Carman, R.J. Clostridium perfringens in spontaneous and antibiotic-associated diarrhoea of man and other
animals. Rev. Med. Microbiol. 1997, 8 (Suppl. S1), S43–S45. [CrossRef]
Toxins 2016, 8, 341 13 of 15
26. Li, J.; Paredes-Sabja, D.; Sarker, M.; Mcclane, B. Clostridium perfringens sporulation and sporulation-associated
toxin production. Microbiol. Spectr. 2016, 4. [CrossRef]
27. Li, J.; McClane, B.A. A novel small acid soluble protein variant is important for spore resistance of most
Clostridium perfringens food poisoning isolates. PLoS Pathog. 2008, 4, e1000056. [CrossRef] [PubMed]
28. Severi, E.; Hood, D.W.; Thomas, G.H. Sialic acid utilization by bacterial pathogens. Microbiology 2007, 153,
2817–2822. [CrossRef] [PubMed]
29. Traving, C.; Schauer, R. Structure, function and metabolism of sialic acids. Cell. Mol. Life Sci. 1998, 54,
1330–1349. [CrossRef] [PubMed]
30. Lewis, A.L.; Lewis, W.G. Host sialoglycans and bacterial sialidases: A mucosal perspective. Cell. Microbiol.
2012, 14, 1174–1182. [CrossRef] [PubMed]
31. Vimr, E.R.; Kalivada, K.A.; Deszo, E.L.; Steenbergen, S.M. Diversity of microbial sialic acid metabolism.
Microbiol. Molec Biol. Rev. 2004, 68, 132–153. [CrossRef]
32. Rohmer, L.; Hocquet, D.; Miller, S.I. Are pathogenic bacteria just looking for food? Metabolism and microbial
pathogenesis. Trends Microb. 2011, 19, 341–348. [CrossRef] [PubMed]
33. Li, J.; McClane, B.A. The sialidases of Clostridium perfringens type D strain CN3718 differ in their properties
and sensitivities to inhibitors. Appl. Environ. Microbiol. 2014, 80, 1701–1709. [CrossRef] [PubMed]
34. Li, J.; Sayeed, S.; Robertson, S.; Chen, J.; McClane, B.A. Sialidases affect the host cell adherence and epsilon
toxin-induced cytotoxicity of Clostridium perfringens type D strain CN3718. PLoS Pathog. 2011, 7, e1002429.
[CrossRef] [PubMed]
35. Boraston, A.B.; Ficko-Blean, E.; Healey, M. Carbohydrate recognition by a large sialidase toxin from
Clostridium perfringens. Biochemistry 2007, 46, 11352–11360. [CrossRef] [PubMed]
36. Li, J.; McClane, B.A. Contributions of NanI sialidase to Caco-2 cell adherence by Clostridium perfringens type
A and C strains causing human intestinal disease. Infect Immun. 2014, 82, 4620–4630. [CrossRef] [PubMed]
37. Chiarezza, M.; Lyras, D.; Pidot, S.J.; Flore-Diaz, M.; Awad, M.M.; Kennedy, C.L.; Cordner, L.M.;
Phumoonna, T.; Poon, R.; Hughes, M.L.; et al. The NanI and NanJ sialidases of Clostridium perfringens
are not essential for virulence. Infect Immun. 2009, 77, 4421–4428. [CrossRef] [PubMed]
38. Myers, G.S.; Rasko, D.A.; Cheung, J.K.; Ravel, J.; Seshadri, R.; DeBoy, R.T.; Ren, Q.; Varga, J.;
Awad, M.M.; Brinkac, L.M.; et al. Skewed genomic variability in strains of the toxigenic bacterial pathogen,
Clostridium perfringens. Genome Res. 2006, 16, 1031–1040. [CrossRef] [PubMed]
39. Shimizu, T.; Ohtani, K.; Hirakawa, H.; Ohshima, K.; Yamashita, A.; Shiba, T.; Ogasawara, N.; Hattori, M.;
Kuhara, S.; Hayashi, H. Complete genome sequence of Clostridium perfringens, an anaerobic flesh-eater.
Proc. Natl. Acad. Sci. USA 2002, 99, 996–1001. [CrossRef] [PubMed]
40. Therit, B.; Cheung, J.K.; Rood, J.I.; Melville, S.B. NanR, a transcriptional regulator that binds to the promoters
of genes involved in sialic acid metabolism in the anaerobic pathogen Clostridium perfringens. PLoS ONE
2015, 10, e0133217. [CrossRef] [PubMed]
41. Ohtani, K.; Hirakawa, H.; Tashiro, K.; Yoshizawa, S.; Kuhara, S.; Shimizu, T. Identification of a
two-component VirR/VirS regulon in Clostridium perfringens. Anaerobe 2010, 16, 258–264. [CrossRef]
[PubMed]
42. Ohtani, K.; Shimizu, T. Regulation of toxin gene expression in Clostridium perfringens. Res. Microbiol. 2014,
166, 280–289. [CrossRef] [PubMed]
43. Hiscox, T.J.; Harrison, P.F.; Chakravorty, A.; Choo, J.M.; Ohtani, K.; Shimizu, T.; Cheung, J.K.; Rood, J.I.
Regulation of sialidase production in Clostridium perfringens by the orphan sensor histidine kinase ReeS.
PLoS ONE 2013, 8, e73525. [CrossRef] [PubMed]
44. Hiscox, T.J.; Chakravorty, A.; Choo, J.M.; Ohtani, K.; Shimizu, T.; Cheung, J.K.; Rood, J.I. Regulation of
virulence by the RevR response regulator in Clostridium perfringens. Infect. Immun. 2011, 79, 2145–2153.
[CrossRef] [PubMed]
45. Li, J.; Ma, M.; Sarker, M.R.; McClane, B.A. CodY is a global regulator of virulence-associated properties for
Clostridium perfringens type D strain CN3718. mBio 2013, 4, e00770–e00713. [CrossRef] [PubMed]
46. Walters, D.M.; Stirewalt, V.L.; Melville, S.B. Cloning, sequence, and transcriptional regulation of the operon
encoding a putative N-acetyl-mannosamine-6-phosphate epimerase (nanE) and sialic acid lyase (nanA) in
Clostridium perfringens. J. Bacteriol. 1999, 181, 4526–4532. [PubMed]
47. Olson, M.E.; King, J.M.; Yahr, T.L.; Horswill, A.R. Sialic acid catabolism in Staphylococcus aureus. J. Bacteriol.
2013, 195, 1779–1788. [CrossRef] [PubMed]
Toxins 2016, 8, 341 14 of 15
48. Almagro-Moreno, S.; Boyd, E.F. Bacterial catabolism of nonulosonic (sialic) acid and fitness in the gut.
Gut Microbes 2010, 1, 45–50. [CrossRef] [PubMed]
49. Almagro-Moreno, S.; Boyd, E.F. Sialic acid catabolism confers a competitive advantage to pathogenic
Vibrio cholerae in the mouse intestine. Infect. Immun. 2009, 77, 3807–3816. [CrossRef] [PubMed]
50. Ng, K.M.; Ferreyra, J.A.; Higginbottom, S.K.; Lynch, J.B.; Kashyap, P.C.; Gopinath, S.; Naidu, N.;
Choudhury, B.; Weimer, B.C.; Monack, D.M.; et al. Microbiota-liberated host sugars facilitate post-antibiotic
expansion of enteric pathogens. Nature 2013, 502, 96–99. [CrossRef] [PubMed]
51. Ley, R.E. Harnessing microbiota to kill a pathogen: The sweet tooth of Clostridium difficile. Nat. Med. 2014, 20,
248–249. [CrossRef] [PubMed]
52. Brittan, J.; Bucheridge, T.; Finn, A.; Kadioglu, A.; Jenkinson, H. Pneumococcal neuraminidase A: An essential
upper airway colonization factor for Streptococcus pneumoniae. Mol. Oral Microb. 2012, 27, 270–283. [CrossRef]
[PubMed]
53. Awad, M.M.; Singleton, J.; Lyras, D. The sialidase NanS enhances non-TcsL mediated cytotoxicity of
Clostridium sordellii. Toxins 2016, 8. [CrossRef] [PubMed]
54. Chang, D.E.; Smalley, D.J.; Tucker, D.L.; Leatham, M.P.; Norris, W.E.; Stevenson, S.J.; Anderson, A.B.;
Grissom, J.E.; Laux, D.C.; Cohen, P.S.; et al. Carbon nutrition of Escherichia coli in the mouse intestine.
Proc. Natl. Acad. Sci. USA 2004, 101, 7427–7432. [CrossRef] [PubMed]
55. Galen, J.E.; Ketley, J.M.; Fasano, A.; Richardson, S.H.; Wasserman, S.S.; Kaper, J.B. Role of Vibrio cholerae
neuraminidase in the fuction of cholera toxin. Infect. Immun. 1992, 60, 406–415. [PubMed]
56. Jeong, H.G.; Oh, M.H.; Kim, B.S.; Lee, M.Y.; Han, H.J.; Choi, S.H. The capability of catabolic utilization of
N-acetylneuraminic acid, a sialic acid, is essential for Vibrio vulnificus pathogenesis. Infect. Immun. 2009, 77,
3209–3217. [CrossRef] [PubMed]
57. Li, J.; Freedman, J.C.; McClane, B.A. NanI sialidase, CcpA, and CodY work together to regulate epsilon toxin
production by Clostridium perfringens type D strain CN3718. J. Bacteriol. 2015, 197, 3339–3353. [CrossRef]
[PubMed]
58. Shimanoto, S.; Tamai, E.; Matsushita, O.; Minami, J.; Okabe, A.; Miyata, S. Changes in ganglioside content
affect the binding of Clostridium perfringens epsilon-toxin to detergent-resistant membranes of Madin-Darby
canine kidney cells. Microbiol. Immun. 2005, 49, 245–253. [CrossRef]
59. Nagahama, M.; Sakurai, J. High-affinity binding of Clostridium perfingens epsilon-toxin to rat brain.
Infect. Immun. 1992, 60, 1237–1240. [PubMed]
60. Jost, B.H.; Billington, S.J.; Trinh, H.T.; Songer, J.G. Association of genes encoding beta2 toxin and a collagen
binding protein in Clostridium perfringens isolates of porcine origin. Vet. Microbiol. 2006, 115, 173–182.
[CrossRef] [PubMed]
61. Hitsumoto, Y.; Morita, N.; Yamazoe, R.; Tagomori, M.; Yamasaki, T.; Katayama, S. Adhesive properties of
Clostridium perfringens to extracellular matrix proteins collagens and fibronectin. Anaerobe 2014, 25, 67–71.
[CrossRef] [PubMed]
62. Katayama, S.; Tagomori, M.; Morita, N.; Yamasaki, T.; Nariya, H.; Okada, M.; Watanabe, M.; Hitsumoto, Y.
Determination of the Clostridium perfringens-binding site on fibronectin. Anaerobe 2015, 34, 174–181.
[CrossRef] [PubMed]
63. Wade, B.; Keyburn, A.L.; Haring, V.; Ford, M.; Rood, J.I.; Moore, R.J. The adherent abilities of
Clostridium perfringens strains are critical for the pathogenesis of avian necrotic enteritis. Vet. Microbiol. 2016,
197, 53–61. [CrossRef]
64. Cioffi, D.L.; Pandey, S.; Alvarez, D.F.; Cioffi, E.A. Terminal sialic acids are an important determinant of
pulmonary endothelial barrier integrity. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 302, L1067–1077.
[CrossRef] [PubMed]
65. Freedman, J.C.; Li, J.; Uzal, F.A.; McClane, B.A. Proteolytic processing and activation of Clostridium perfringens
epsilon toxin by caprine small intestinal contents. mBio 2014, 5, e01994–e01914. [CrossRef] [PubMed]
66. Hanna, P.C.; Wieckowski, E.U.; Mietzner, T.A.; McClane, B.A. Mapping functional regions of
Clostridium perfringens type A enterotoxin. Infect. Immun. 1992, 60, 2110–2114. [PubMed]
67. Streicher, H. Inhibition of microbial sialidases-what has happened beyond the influenza virus? Curr. Med.
Chem. Anti-Infect. Agents 2004, 3, 149–161. [CrossRef]
68. Roy, S.; Honma, K.; Douglas, C.W.; Sharma, A.; Stafford, G.P. Role of sialidase in glycoprotein utilization by
Tannerella forsythia. Microbiology 2011, 157, 3195–3202. [CrossRef] [PubMed]
Toxins 2016, 8, 341 15 of 15
69. Holzer, C.T.; von Itzstein, M.; Jin, B.; Pegg, M.S.; Stewart, W.P.; Wu, W.Y. Inhibition of sialidases from viral,
bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified
at the C-4 position. Glycoconj. J. 1993, 10, 40–44. [CrossRef] [PubMed]
70. Knapp, S.; Zhao, D. Synthesis of the sialidase inhibitor siastatin B. Org. Lett. 2000, 2, 4037–4040. [CrossRef]
[PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
